Bod Australia Limited (“Bod”, the “Company”) (ASX: BDA), will be participating in Project Twenty21, Europe’s largest medicinal cannabis project, which will study the effects of cannabis when used on patients with chronic conditions. Project Twenty21 is a UK based study which will enrol 20,000 patients by the end of 2021 to create the largest body of evidence for the efficacy of medicinal cannabis.
The purpose of Project Twenty21
The aim is to utilise collated data to convince policy makers that medicinal cannabis should be made more readily available, and affordable, for patients who would benefit from it across the UK. Further, the project aims to assist prescribers operating in the region and advance the potential for NHS funding.
Bod Australia is 1 in only 5 companies
Bod is one of five companies invited to participate in Project Twenty21 and is aiming to treat a minimum of 1,000 patients with its MediCabilis™ CBD product (“MediCabilis™”). The Company will receive a cost per prescription for each MediCabilis™ unit sold.